Fukumura, Kazutaka
Malgulwar, Prit Benny
Fischer, Grant M.
Hu, Xiaoding
Mao, Xizeng
Song, Xingzhi
Hernandez, Sharia D.
Zhang, Xiang H.-F.
Zhang, Jianhua
Parra, Edwin Roger
Yu, Dihua
Debeb, Bisrat G.
Davies, Michael A.
Huse, Jason T. http://orcid.org/0000-0003-4440-3250
Funding for this research was provided by:
National Institutes of Health (P30 CA016672)
American Cancer Society
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
University of Texas MD Anderson Cancer Center
AIM at Melanoma
Susan G. Komen
Taiho Pharmaceutical
Cancer Fighters of Houston
Anne and John Mendelsohn Chair in Cancer Research
Melanoma Research Alliance
Article History
Received: 7 October 2020
Revised: 28 November 2020
Accepted: 18 December 2020
First Online: 4 January 2021
Compliance with ethical standards
:
: M.A.D. receives commercial research grants from AstraZeneca, Roche/Genentech, GlaxoSmithKline, Myriad, Oncothyreon, and Sanofi-Aventis and is a consultant/advisory board member for GlaxoSmithKline, Novartis, Roche/Genentech, Array, Bristol-Myers Squibb, Sanofi-Aventis, Vaccinex, Syndax, and NanoString. All other authors declare no conflict of interest.